The Importance of Antiviral Prophylaxis against Hepatitis B Virus in Patients under Immunosuppressive Therapy

AKSOY F., KAYA S., Karakoc H. N., YILMAZ G., Atalar S., Koksal I.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.25, sa.2, ss.50-54, 2019 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 2
  • Basım Tarihi: 2019
  • Doi Numarası: 10.4274/vhd.galenos.2019.2018.0027
  • Dergi Adı: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.50-54
  • Anahtar Kelimeler: Hepatitis B virus, prophylaxis, immunosuppressive therapy, REACTIVATION, MANAGEMENT, INFECTION, GUIDELINES
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Objectives: Immunosuppressive (IS) therapies present a risk of reactivation in patients with previous or known hepatitis B virus (HBV) infection and may cause mortality and morbidity. Before starting these therapies, patients should be tested for HBV serology and evaluated for antiviral therapy.